{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:10:02Z","timestamp":1780319402379,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12325-017-0514-y","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T14:05:14Z","timestamp":1489673114000},"page":"854-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Impact of Antibiotic Stewardship Programs in Combating Quinolone Resistance: A Systematic Review and Recommendations for More Efficient Interventions"],"prefix":"10.1007","volume":"34","author":[{"given":"Vasiliki","family":"Pitiriga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Vrioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Saroglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"issue":"8","key":"514_CR1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/512810","volume":"44","author":"H Goossens","year":"2007","unstructured":"Goossens H, Ferech M, Coenen S, Stephens P, European Surveillance of Antimicrobial Consumption Project Group. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis. 2007;44(8):1091\u20135.","journal-title":"Clin Infect Dis"},{"issue":"41 Suppl 2","key":"514_CR2","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","volume":"15","author":"RC Owens","year":"2005","unstructured":"Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;15(41 Suppl 2):S144\u201357.","journal-title":"Clin Infect Dis"},{"key":"514_CR3","unstructured":"European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2012. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/antimicrobial-resistance-surveillance-europe-2012.pdf . Accessed 2 Dec 2014."},{"issue":"11","key":"514_CR4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid0911.030284","volume":"9","author":"SG Weber","year":"2003","unstructured":"Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis. 2003;9(11):1415\u201322.","journal-title":"Emerg Infect Dis"},{"key":"514_CR5","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1086\/521859","volume":"46","author":"RA Owens","year":"2008","unstructured":"Owens RA, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:S19\u201331.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"514_CR6","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/AAC.00464-08","volume":"52","author":"K Tanimoto","year":"2008","unstructured":"Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y. Fluoroquinolones enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob Agents Chemother. 2008;52(10):3795\u2013800.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10 Suppl 2","key":"514_CR7","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.ajic.2007.10.006","volume":"35","author":"JD Siegel","year":"2007","unstructured":"Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35(10 Suppl 2):S165\u201393.","journal-title":"Am J Infect Control"},{"issue":"2","key":"514_CR8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","volume":"44","author":"TH Dellit","year":"2007","unstructured":"Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159\u201377.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"514_CR9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/jac\/dkh163","volume":"53","author":"PP Cook","year":"2004","unstructured":"Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother. 2004;53(5):853\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"514_CR10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1086\/500319","volume":"42","author":"P Charbonneau","year":"2006","unstructured":"Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis. 2006;42(6):778\u201384.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"514_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/500060","volume":"27","author":"KJ Madaras-Kelly","year":"2006","unstructured":"Madaras-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol. 2006;27(2):155\u201369.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"514_CR12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkh039","volume":"53","author":"AH Mutnick","year":"2004","unstructured":"Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999\u20132001). J Antimicrob Chemother. 2004;53(2):290\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"514_CR13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(01)02130-8","volume":"9","author":"M Lipsitch","year":"2001","unstructured":"Lipsitch M. The rise and fall of antimicrobial resistance. Trends Microbiol. 2001;9(9):438\u201344.","journal-title":"Trends Microbiol"},{"key":"514_CR14","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1086\/499407","volume":"42","author":"DL Paterson","year":"2006","unstructured":"Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis. 2006;42:S90\u20135.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"514_CR15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1086\/589813","volume":"29","author":"PP Cook","year":"2008","unstructured":"Cook PP, Das TD, Gooch M, Catrou PG. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents. Infect Control Hosp Epidemiol. 2008;29(8):716\u201322.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"514_CR16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1086\/500319","volume":"42","author":"P Charbonneau","year":"2006","unstructured":"Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis. 2006;42(6):778\u201384.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"514_CR17","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/jac\/dkr253","volume":"66","author":"MJ Talpaert","year":"2011","unstructured":"Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother. 2011;66(9):2168\u201374.","journal-title":"J Antimicrob Chemother"},{"key":"514_CR18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","volume":"34","author":"DM Livermore","year":"2002","unstructured":"Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634\u201340.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"514_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhin.2004.07.016","volume":"59","author":"G Aubert","year":"2005","unstructured":"Aubert G, Carricajo A, Vautrin AC, Guyomarch S, et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect. 2005;59(2):83\u20139.","journal-title":"J Hosp Infect"},{"issue":"3 Pt 1","key":"514_CR20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1164\/ajrccm.162.3.9905050","volume":"162","author":"D Gruson","year":"2000","unstructured":"Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram negative bacteria. Am J Respir Crit Care Med. 2000;162(3 Pt 1):837\u201343.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"514_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijantimicag.2009.11.007","volume":"35","author":"YJ Lee","year":"2010","unstructured":"Lee YJ, Liu HY, Lin YC, Sun KL, Chun CL, Hsueh PR. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. Int J Antimicrob Agents. 2010;35(3):261\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"514_CR22","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/jac\/dks083","volume":"67","author":"AL Pakyz","year":"2012","unstructured":"Pakyz AL, Lee JA, Ababneh MA, Harpe SE, Oinonen MJ, Polk RE. Fluoroquinolone use and fluoroquinolone-resistant Pseudomonas aeruginosa is declining in US academic medical centre hospitals. J Antimicrob Chemother. 2012;67(6):1562\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"514_CR23","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/jac\/dkr555","volume":"67","author":"M Lafaurie","year":"2012","unstructured":"Lafaurie M, Porcher R, Donay JL, Touratier S, Molina JM. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10\u00a0year study. J Antimicrob Chemother. 2012;67(4):1010\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"514_CR24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1086\/664763","volume":"33","author":"GJ Lewis","year":"2012","unstructured":"Lewis GJ, Fang X, Gooch M, Cook PP. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital\u2019s intensive care and intermediate care units. Infect Control Hosp Epidemiol. 2012;33(4):368\u201373.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"514_CR25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0924-8579(98)00045-4","volume":"10","author":"LR Peterson","year":"1998","unstructured":"Peterson LR, Postelnick M, Pozdol TL, Reisberg B, Noskin GA. Management of fluoroquinolone resistance in Pseudomonas aeruginosa\u2014outcome of monitored use in a referral hospital. Int J Antimicrob Agents. 1998;10:207\u201314.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"514_CR26","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/jac\/dkw055","volume":"71","author":"J Boel","year":"2016","unstructured":"Boel J, Andreasen V, Jarl\u00f8v JO, et al. Impact of antibiotic restriction on resistance levels of Escherichia coli: a controlled interrupted-time series study of a hospital-wide antibiotic stewardship programme. J Antimicrob Chemother. 2016;71(7):2047\u201351.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"514_CR27","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/AAC.01581-09","volume":"54","author":"I Willemsen","year":"2010","unstructured":"Willemsen I, Cooper B, van Buitenen C, Winters M, Andriesse G, Kluytmans J. Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis. Antimicrob Agents Chemother. 2010;54(9):3763\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"514_CR28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/605530","volume":"49","author":"BS Gottesman","year":"2009","unstructured":"Gottesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis. 2009;49(6):869\u201375.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"514_CR29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jhin.2015.05.006","volume":"91","author":"JB Sarma","year":"2015","unstructured":"Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T, Woolfrey S. Effects of fluoroquinolone restriction (from 2007 to 2012) on resistance in Enterobacteriaceae. J Hosp Infect. 2015;91(1):68\u201373.","journal-title":"J Hosp Infect"},{"issue":"9","key":"514_CR30","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/jac\/dkr264","volume":"66","author":"JA Troughton","year":"2011","unstructured":"Troughton JA, Millar G, Smyth ET, Doherty L, McMullan R. Ciprofloxacin use and susceptibility of gram-negative organisms to quinolone and non-quinolone antibiotics. J Antimicrob Chemother. 2011;66(9):2152\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"514_CR31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2125.2011.04161.x","volume":"74","author":"MA Aldeyab","year":"2012","unstructured":"Aldeyab MA, Harbarth S, Vernaz N, et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74(1):171\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"514_CR32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhin.2011.03.008","volume":"78","author":"JJ Parienti","year":"2011","unstructured":"Parienti JJ, Cattoir V, Thibon P, et al. Hospital-wide modification of fluoroquinolone policy and methicillin-resistant Staphylococcus aureus rates: a 10-year interrupted time-series analysis. J Hosp Infect. 2011;78(2):118\u201322.","journal-title":"J Hosp Infect"},{"issue":"4","key":"514_CR33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jhin.2008.04.026","volume":"69","author":"LD Liebowitz","year":"2008","unstructured":"Liebowitz LD, Blunt MC. Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in methicillin-resistant Staphylococcus aureus bacteraemia rate. J Hosp Infect. 2008;69(4):328\u201336.","journal-title":"J Hosp Infect"},{"issue":"2","key":"514_CR34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijantimicag.2012.10.013","volume":"41","author":"SJ Dancer","year":"2013","unstructured":"Dancer SJ, Kirkpatrick P, Corcoran DS, Christison F, Farmer D, Robertson C. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum \u03b2-lactamase-producing coliforms and methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2013;41(2):137\u201342.","journal-title":"Int J Antimicrob Agents"},{"key":"514_CR35","doi-asserted-by":"crossref","unstructured":"Tedeschi S, Trapani F, Giannella M, et al. An antimicrobial stewardship program based on systematic infectious disease consultation in a rehabilitation facility. Infect Control Hosp Epidemiol. 2017;38:76\u201382.","DOI":"10.1017\/ice.2016.233"},{"issue":"9","key":"514_CR36","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/jac\/dkr253","volume":"66","author":"MJ Talpaert","year":"2011","unstructured":"Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother. 2011;66(9):2168\u201374.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"514_CR37","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1128\/AAC.03006-14","volume":"58","author":"JM Wenisch","year":"2014","unstructured":"Wenisch JM, Equiluz-Bruck S, Fudel M, et al. Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use. Antimicrob Agents Chemother. 2014;58(9):5079\u201383.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"514_CR38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/MMBR.00016-10","volume":"74","author":"J Davies","year":"2010","unstructured":"Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol. 2010;74(3):417\u201333.","journal-title":"Microbiol Mol Biol"},{"issue":"5","key":"514_CR39","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1128\/AAC.01131-09","volume":"54","author":"KM Wener","year":"2010","unstructured":"Wener KM, Schechner V, Gold HS, Wright SB, Carmeli Y. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010;54(5):2010\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"514_CR40","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1128\/AAC.00155-06","volume":"50","author":"MI Morosini","year":"2006","unstructured":"Morosini MI, Garcia-Castillo M, Coque TM, et al. Antibiotic co-resistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother. 2006;50(8):2695\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"514_CR41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0732-8893(01)00357-1","volume":"42","author":"J Ruiz","year":"2002","unstructured":"Ruiz J, G\u00f3mez J, Navia MM, et al. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis. 2002;42(4):257\u201361.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 3","key":"514_CR42","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0924-8579(10)70005-4","volume":"36","author":"RG Masterton","year":"2010","unstructured":"Masterton RG. Antibiotic heterogeneity. Int J Antimicrob Agents. 2010;36(Suppl 3):S15\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"514_CR43","doi-asserted-by":"crossref","first-page":"e0150274","DOI":"10.1371\/journal.pone.0150274","volume":"11","author":"N Cobos-Trigueros","year":"2016","unstructured":"Cobos-Trigueros N, Sol\u00e9 M, Castro P, et al. Evaluation of a mixing versus a cycling strategy of antibiotic use in critically-ill medical patients: impact on acquisition of resistant microorganisms and clinical outcomes. PLoS One. 2016;11(3):e0150274.","journal-title":"PLoS One"},{"issue":"6","key":"514_CR44","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/jac\/dkl097","volume":"57","author":"A Sandiumenge","year":"2006","unstructured":"Sandiumenge A, Diaz E, Rodriguez A, et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother. 2006;57(6):1197\u2013204.","journal-title":"J Antimicrob Chemother"},{"key":"514_CR45","unstructured":"Infectious Diseases Society of America. New antibiotic stewardship guidelines focus on practical advice for implementation. IDSA. 14 Apr 2016. https:\/\/www.idsociety.org\/New_Antimicrobial_Stewardship_Guideline_2016 . Accessed 3 Mar 2017."},{"key":"514_CR46","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1128\/JCM.00313-13","volume":"51","author":"A Belkum van","year":"2013","unstructured":"van Belkum A, Dunne WM. Next-generation antimicrobial susceptibility testing. J Clin Microbiol. 2013;51:2018\u201324.","journal-title":"J Clin Microbiol"},{"key":"514_CR47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13756-015-0087-y","volume":"4","author":"A Agodi","year":"2015","unstructured":"Agodi A, Barchitta M, Quattrocchi A, et al. Antibiotic trends of Klebsiella pneumoniae and Acinetobacter baumannii resistance indicators in an intensive care unit of Southern Italy, 2008\u20132013. Antimicrob Resist Infect Control. 2015;4:43.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"514_CR48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/fmb.14.127","volume":"10","author":"A Cohen","year":"2015","unstructured":"Cohen A, Bont L, Engelhard D. A multifaceted \u2018omics\u2019 approach for addressing the challenge of antimicrobial resistance. Future Microbiol. 2015;10(3):365\u201376.","journal-title":"Future Microbiol"},{"issue":"1","key":"514_CR49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/fmb.15.99","volume":"11","author":"JWH Dik","year":"2016","unstructured":"Dik JWH, Poelman R, Friedrich AW, et al. An integrated stewardship model: antimicrobial, infection prevention and diagnostic (AID). Future Microbiol. 2016;11(1):93\u2013102.","journal-title":"Future Microbiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0514-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T20:49:40Z","timestamp":1568926180000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0514-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0514-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}